Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 21, 2017; 23(23): 4181-4190
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4181
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4181
Figure 4 Intervention with Senicapoc is anti-steatotic in the CDAHFD Model.
In animals randomized to Senicapoc for 4 wk after 4 wk on CDAHFD (total 8 wk on diet), A: Reduced NAS (0-8 scale); B: Reduced steatosis (0-3 scale); and (C) reduced accumulation of hepatic triglycerides was observed. aP < 0.05 vs CDAHFD + vehicle.
- Citation: Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017; 23(23): 4181-4190
- URL: https://www.wjgnet.com/1007-9327/full/v23/i23/4181.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i23.4181